Ankylosing Spondylitis Forecast in 13 Major Markets 2017-2027: Focus on USA, Canada, France, Germany, Italy, Spain, UK, Russia, Turkey, Brazil, Japan, India and China - Research and Markets

Friday, April 14, 2017

DUBLIN--(BUSINESS WIRE)-- Research and Markets has announced the addition of the "Ankylosing Spondylitis Forecast in 13 Major Markets 2017-2027" report to their offering.

Ankylosing Spondylitis (AkS) is a chronic, systemic inflammatory autoimmune disease. It primarily affects the sacro-iliac joints of the hip and pelvis, but extends to the axial skeleton. Patients experience low back pain and increased stiffness.

This report provides the current prevalent population for Ankylosing Spondylitis across 13 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Turkey, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Ankylosing Spondylitis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

There are several features associated with Ankylosing Spondylitis, these include:

- Psoriasis

- Uveitis


- Enthesitis

- Peripheral arthritis

- Pulmonary fibrosis

- CVD (aortic root / rheumatic heart / AV block and other conduction disorders)

- Prostatitis (males)

- Spinal ankylosis and fracture

Key Topics Covered:

1. Introduction

2. Cause of the Disease

3. Risk Factors & Prevention

4. Diagnosis of the Disease

5. Variation by Geography/Ethnicity

6. Disease Prognosis & Clinical Course

7. Key comorbid conditions/Features associated with the disease

8. Methodology for quantification of patient numbers

9. Top-line prevalence for Ankylosing Spondylitis

10. Features of Ankylosing Spondylitis Patients

11. Abbreviations used in the report

12. Patient-Based Offering

13. Online Pricing Data and Platforms

14. References

15. Appendix

For more information about this report visit